Rational design of a genomically humanized mouse model for dominantly inherited hearing loss, DFNA9
DFNA9 is a dominantly inherited form of adult-onset progressive hearing impairment caused by mutations in the COCH gene. COCH encodes cochlin, a crucial extracellular matrix protein. We established a genomically humanized mouse model for the Dutch/Belgian c.151C>T founder mutation in COCH. Considering upcoming sequence-specific genetic therapies, we exchanged the genomic murine Coch exons 3–6 for the corresponding human sequence. Introducing human-specific genetic information into mouse exons can be risky. To mitigate unforeseen consequences on cochlin function resulting from the introduction of the human COCH protein-coding sequence, we converted all human-specific amino acids to mouse equivalents. We furthermore optimized the recognition of the human COCH exons by the murine splicing machinery during pre-mRNA splicing. Subsequent observations in mouse embryonic stem cells revealed correct splicing of the hybrid Coch transcript. The inner ear of the established humanized Coch mice displays correctly-spliced wild-type and mutant humanized Coch alleles. For a comprehensive study of auditory function, mice were crossbred with C57BL/6 Cdh23753A>G mice to remove the Cdh23ahl allele from the genetic background of the mice. At 9 months, all humanized Coch genotypes showed hearing thresholds comparable to wild-type C57BL/6 Cdh23753A>G mice. This indicates that both the introduction of human wildtype COCH, and correction of Cdh23ahl in the humanized Coch lines was successful. Overall, our approach proved beneficial in eliminating potential adverse events of genomic humanization of mouse genes, and provides us with a model in which sequence-specific therapies directed against the human mutant COCH alle can be investigated. With the hearing and balance defects anticipated to occur late in the second year of life, a long-term follow-up study is ongoing to fully characterize the humanized Coch mouse model.
Source (journal)
Hearing research. - Amsterdam
Amsterdam : 2024
442 (2024) , p. 1-13
Article Reference
Pubmed ID
Full text (Publisher's DOI)
Full text (open access)
Research group
Project info
Inner ear gene therapy to prevent deafness in DFNA9.
Delivery of CRISPR-Cas9 mRNA-based therapy into the inner ear by lipid nanoparticles: Cure deafness by disrupting mutant COCH expression in a humanized DFNA9 mouse model.
Development of allele-specific crispr-nuclease gene therapy for late-onset sensorineural hearing impairment in a humanized dfna9 mouse model.
Cognition and Auditory-Evoked Potentials in DFNA9 Patients and Humanized Mice - From Normal Function to Adult-Onset Otovestibular Decline
The humanized dfna9 mouse model as a novel approach to identify tissue-specific and blood-based bio-assays that reflect human dfna9 pathophysiology and to test crispr/cas systems to prevent hearing loss.
Publication type
Publications with a UAntwerp address
External links
Creation 15.01.2024
Last edited 16.01.2024
To cite this reference